{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-067461","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.032003+00:00","generated_at":"2026-06-07T18:47:12.511246+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IDEAYA collaborates with Gilead for Phase 1 combo of IDE397 + Trodelvy in MTAP-deletion bladder cancer","bullets":["IDEAYA and Gilead will evaluate IDE397 (MAT2A inhibitor) plus Trodelvy (Trop-2 ADC) in MTAP-deletion bladder cancer.","MTAP-deletion prevalence in bladder cancer is ~26%, with no approved therapies for this population.","IDEAYA sponsors the Phase 1 trial; Gilead provides Trodelvy at no cost; each party retains commercial rights to its own compound.","IDEAYA is also evaluating IDE397 in an ongoing Phase 1/2 monotherapy and in a separate Amgen combination study."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-067461","json":"https://secwatch.observer/filing/0000950170-23-067461.json","markdown":"https://secwatch.observer/filing/0000950170-23-067461.md","text":"https://secwatch.observer/filing/0000950170-23-067461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023067461/0000950170-23-067461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023067461/idya-20231129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:47:12.511246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}